Acadia Pharmaceuticals Inc
ACAD· Nasdaq
ACADAcadia Pharmaceuticals Inc
Released Feb 24, 2021, after the close
10-K filed Feb 25, 2021, 56 days after period end · 0001564590-21-008372
derived · Computed from the longer spans the company filed.
| Metric | Q4 2020dderived from reported figures | Q4 2019 | Q4 2018 | Q4 2017 |
|---|---|---|---|---|
| Revenue | $121.01M | $98.33M | $59.57M | $43.56M |
| Net Income | -$66.76M | -$53.04M | -$65.49M | -$68.87M |
Acadia Pharmaceuticals Inc · CIK 1070494 · Engraved from SEC EDGAR
| EPS Diluted | — | -$0.34 | -$0.50 | -$0.55 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
